ArticleThe Lancet. Oncology2023

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.

Kazuki Nozawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.